{"title":"Is It Time to Retire the Unified Cancer of Unknown Primary Concept in the Precision Oncology Era?","authors":"Vivek Subbiah,F Anthony Greco","doi":"10.1200/jco-25-02189","DOIUrl":"https://doi.org/10.1200/jco-25-02189","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":"4 1","pages":"JCO2502189"},"PeriodicalIF":45.3,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145955499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Floris J Pos,Karolína Menne Guricová,Jochem R N van der Voort van der Zyp,Robert J Smeenk,Uulke A van der Heide,Karin Haustermans,Cédric Draulans
{"title":"Reply to: Focal Boosting in Localized Prostate Cancer in the Era of Systemic Therapy and Prostate-Specific Membrane Antigen Imaging.","authors":"Floris J Pos,Karolína Menne Guricová,Jochem R N van der Voort van der Zyp,Robert J Smeenk,Uulke A van der Heide,Karin Haustermans,Cédric Draulans","doi":"10.1200/jco-25-02744","DOIUrl":"https://doi.org/10.1200/jco-25-02744","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":"94 1","pages":"JCO2502744"},"PeriodicalIF":45.3,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145956179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Can Pathologic Complete Response Serve as a Valid Surrogate End Point?","authors":"Doga Kahramangil,Ilyas Sahin","doi":"10.1200/jco-25-02070","DOIUrl":"https://doi.org/10.1200/jco-25-02070","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":"39 1","pages":"JCO2502070"},"PeriodicalIF":45.3,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145955938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-10Epub Date: 2025-12-01DOI: 10.1200/JCO-25-02762
Pau Montesinos, Rebeca Rodríguez-Veiga, Juan Miguel Bergua, Jesús Lorenzo Algarra Algarra, Carmen Botella, Eduardo Rodríguez-Arbolí, Teresa Bernal, Mar Tormo, Maria Calbacho, Olga Salamero, Josefina Serrano, Victor Noriega, Juan Antonio López-López, Susana Vives, Jose Luis López-Lorenzo, Mercedes Colorado, Maria-Belén Vidriales, Raimundo García Boyero, Maria Teresa Olave, Pilar Herrera, Olga Arce, Manuel Barrios, Maria Jose Sayas, Marta Polo, Maria Isabel Gómez-Roncero, Eva Barragán, Rosa Ayala, Carmen Chillón, Maria José Calasanz, Bruno Paiva, Blanca Boluda, Ignacio Casas-Avilés, Pilar Lloret, Maria-José Sánchez, Carlos Rodríguez-Medina, Laida Cuevas, José Ángel Raposo-Puglia, M Carmen Mateos, Matxalen Olivares, Carmen Martínez-Chamorro, Natalia Alonso, Sandra Suárez, Irene Sánchez-Vadillo, María Solé Rodríguez, Bernardo Javier González, Antonio Martínez-Francés, Rebeca Cuello, Alfonso Fernández, David Martínez-Cuadrón, Jorge Labrador
{"title":"Erratum: Quizartinib for Newly Diagnosed <i>FLT3</i>-Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study.","authors":"Pau Montesinos, Rebeca Rodríguez-Veiga, Juan Miguel Bergua, Jesús Lorenzo Algarra Algarra, Carmen Botella, Eduardo Rodríguez-Arbolí, Teresa Bernal, Mar Tormo, Maria Calbacho, Olga Salamero, Josefina Serrano, Victor Noriega, Juan Antonio López-López, Susana Vives, Jose Luis López-Lorenzo, Mercedes Colorado, Maria-Belén Vidriales, Raimundo García Boyero, Maria Teresa Olave, Pilar Herrera, Olga Arce, Manuel Barrios, Maria Jose Sayas, Marta Polo, Maria Isabel Gómez-Roncero, Eva Barragán, Rosa Ayala, Carmen Chillón, Maria José Calasanz, Bruno Paiva, Blanca Boluda, Ignacio Casas-Avilés, Pilar Lloret, Maria-José Sánchez, Carlos Rodríguez-Medina, Laida Cuevas, José Ángel Raposo-Puglia, M Carmen Mateos, Matxalen Olivares, Carmen Martínez-Chamorro, Natalia Alonso, Sandra Suárez, Irene Sánchez-Vadillo, María Solé Rodríguez, Bernardo Javier González, Antonio Martínez-Francés, Rebeca Cuello, Alfonso Fernández, David Martínez-Cuadrón, Jorge Labrador","doi":"10.1200/JCO-25-02762","DOIUrl":"10.1200/JCO-25-02762","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"134"},"PeriodicalIF":41.9,"publicationDate":"2026-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145653322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Gunsagar S Gulati,Toni K Choueiri,Matthew L Freedman,Sylvan C Baca
{"title":"Precision Oncology 2.0: Guiding Magic Bullets With Expression-Based Liquid Biopsy.","authors":"Gunsagar S Gulati,Toni K Choueiri,Matthew L Freedman,Sylvan C Baca","doi":"10.1200/jco-25-01983","DOIUrl":"https://doi.org/10.1200/jco-25-01983","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":"27 1","pages":"JCO2501983"},"PeriodicalIF":45.3,"publicationDate":"2026-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145937773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sharon M Castellino,Hongli Li,Alex F Herrera,Michael LeBlanc,Susan K Parsons,Joseph M Unger,Angela Punnett,David Hodgson,Frank G Keller,Richard A Drachtman,Adam Lamble,Christopher J Forlenza,Andrew Doan,Sarah C Rutherford,Andrew M Evens,Richard F Little,Malcolm A Smith,Bradford S Hoppe,Joo Y Song,Sonali M Smith,Jonathan W Friedberg,Kara M Kelly
We present a subset analysis on the adolescent cohort of the S1826 randomized phase three trial, comparing nivolumab, doxorubicin, vinblastine, dacarbazine (N-AVD) to brentuximab vedotin-AVD (BV-AVD) in newly diagnosed advanced-stage (AS, stages III and IV) classic Hodgkin lymphoma (cHL). Among 994 patients enrolled, 24% (n = 240) were age 12-17 years. The 3-year progression-free survival (PFS) was significantly higher in the N-AVD group (93% [95% CI, 87 to 96]) compared with the BV-AVD group (82% [95% CI, 73 to 88]; hazard ratio, 0.37 [95% CI, 0.17 to 0.80]). One N-AVD and two BV-AVD patients received protocol-specified residual site radiotherapy (RT). Rates of febrile neutropenia and sepsis were low in both groups. Severe immune-related adverse events were infrequent, although thyroid dysfunction was seen in 7% with N-AVD. Sensory neuropathy (grade ≥2) was more frequent with BV-AVD (14% v 7%) by clinician report. Although premature discontinuation of therapy was reported in 12 N-AVD patients and four BV-AVD patients, no PFS events were noted in the N-AVD group. Patient-reported outcomes indicated less toxicity with N-AVD. N-AVD demonstrated high 3-year PFS in adolescents with AS cHL, with minimal RT use. S1826 exemplifies the benefits of harmonized clinical trial protocols, resulting in timely access to novel agents for adolescents.
{"title":"Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826.","authors":"Sharon M Castellino,Hongli Li,Alex F Herrera,Michael LeBlanc,Susan K Parsons,Joseph M Unger,Angela Punnett,David Hodgson,Frank G Keller,Richard A Drachtman,Adam Lamble,Christopher J Forlenza,Andrew Doan,Sarah C Rutherford,Andrew M Evens,Richard F Little,Malcolm A Smith,Bradford S Hoppe,Joo Y Song,Sonali M Smith,Jonathan W Friedberg,Kara M Kelly","doi":"10.1200/jco-25-00203","DOIUrl":"https://doi.org/10.1200/jco-25-00203","url":null,"abstract":"We present a subset analysis on the adolescent cohort of the S1826 randomized phase three trial, comparing nivolumab, doxorubicin, vinblastine, dacarbazine (N-AVD) to brentuximab vedotin-AVD (BV-AVD) in newly diagnosed advanced-stage (AS, stages III and IV) classic Hodgkin lymphoma (cHL). Among 994 patients enrolled, 24% (n = 240) were age 12-17 years. The 3-year progression-free survival (PFS) was significantly higher in the N-AVD group (93% [95% CI, 87 to 96]) compared with the BV-AVD group (82% [95% CI, 73 to 88]; hazard ratio, 0.37 [95% CI, 0.17 to 0.80]). One N-AVD and two BV-AVD patients received protocol-specified residual site radiotherapy (RT). Rates of febrile neutropenia and sepsis were low in both groups. Severe immune-related adverse events were infrequent, although thyroid dysfunction was seen in 7% with N-AVD. Sensory neuropathy (grade ≥2) was more frequent with BV-AVD (14% v 7%) by clinician report. Although premature discontinuation of therapy was reported in 12 N-AVD patients and four BV-AVD patients, no PFS events were noted in the N-AVD group. Patient-reported outcomes indicated less toxicity with N-AVD. N-AVD demonstrated high 3-year PFS in adolescents with AS cHL, with minimal RT use. S1826 exemplifies the benefits of harmonized clinical trial protocols, resulting in timely access to novel agents for adolescents.","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":"244 1","pages":"JCO2500203"},"PeriodicalIF":45.3,"publicationDate":"2026-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145937769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Timothy Iveson,Mark P Saunders,Caroline Kelly,Rachel S Kerr,Jim Cassidy,Niels Henrik Hollander,Josep Tabernero,Andrew Haydon,Bengt Glimelius,Andrea Harkin,Karen Allan,John McQueen,Sarah Pearson,Kathleen A Boyd,Andrew H Briggs,Ashita Waterston,Louise Medley,Richard Ellis,Amandeep S Dhadda,Mark Harrison,Stephen Falk,Charlotte Rees,Rene K Olesen,David Propper,John Bridgewater,Ashraf Azzabi,David Cunningham,Tamas Hickish,Simon Gollins,Harpreet S Wasan,David Church,Enric Domingo
Adjuvant chemotherapy for colorectal cancer (CRC) with oxaliplatin and fluoropyrimidine was traditionally given for 6 months but is associated with cumulative peripheral neuropathy. The SCOT study (ISRCTN59757862) was an international, randomized, phase III, noninferiority trial investigating treatment reduction from 6 to 3 months. It originally reported noninferior disease-free survival with reduced toxicity and improved quality of life for 3 months of treatment in 6,088 patients. Here, we report overall survival (OS) with 38 months of additional follow-up. Patients with high-risk stage II and stage III CRC were assigned (1:1) to receive 3 or 6 months of either capecitabine and oxaliplatin (CAPOX) or infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX; bolus and infused fluorouracil with oxaliplatin) that were selected before random assignment. With a median of 113 months follow-up and 1,255 OS events, 5-year OS for 3 versus 6 months of treatment was 82.4% in both groups (hazard ratio, 0.96; 95% CI, 0.8 to 1.07), proving noninferiority of 3 months of treatment. Noninferiority of 3 months of treatment for OS was also shown in 1,087 patients with rectal cancer. The duration effect is regimen-dependent with noninferiority shown for CAPOX but not for FOLFOX. In summary, SCOT has shown noninferiority for OS with 3 months of adjuvant chemotherapy treatment, which should be recommended for most patients.
{"title":"Three Versus 6 Months of Adjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT-An International, Randomized, Phase III, Noninferiority Trial.","authors":"Timothy Iveson,Mark P Saunders,Caroline Kelly,Rachel S Kerr,Jim Cassidy,Niels Henrik Hollander,Josep Tabernero,Andrew Haydon,Bengt Glimelius,Andrea Harkin,Karen Allan,John McQueen,Sarah Pearson,Kathleen A Boyd,Andrew H Briggs,Ashita Waterston,Louise Medley,Richard Ellis,Amandeep S Dhadda,Mark Harrison,Stephen Falk,Charlotte Rees,Rene K Olesen,David Propper,John Bridgewater,Ashraf Azzabi,David Cunningham,Tamas Hickish,Simon Gollins,Harpreet S Wasan,David Church,Enric Domingo","doi":"10.1200/jco-25-00621","DOIUrl":"https://doi.org/10.1200/jco-25-00621","url":null,"abstract":"Adjuvant chemotherapy for colorectal cancer (CRC) with oxaliplatin and fluoropyrimidine was traditionally given for 6 months but is associated with cumulative peripheral neuropathy. The SCOT study (ISRCTN59757862) was an international, randomized, phase III, noninferiority trial investigating treatment reduction from 6 to 3 months. It originally reported noninferior disease-free survival with reduced toxicity and improved quality of life for 3 months of treatment in 6,088 patients. Here, we report overall survival (OS) with 38 months of additional follow-up. Patients with high-risk stage II and stage III CRC were assigned (1:1) to receive 3 or 6 months of either capecitabine and oxaliplatin (CAPOX) or infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX; bolus and infused fluorouracil with oxaliplatin) that were selected before random assignment. With a median of 113 months follow-up and 1,255 OS events, 5-year OS for 3 versus 6 months of treatment was 82.4% in both groups (hazard ratio, 0.96; 95% CI, 0.8 to 1.07), proving noninferiority of 3 months of treatment. Noninferiority of 3 months of treatment for OS was also shown in 1,087 patients with rectal cancer. The duration effect is regimen-dependent with noninferiority shown for CAPOX but not for FOLFOX. In summary, SCOT has shown noninferiority for OS with 3 months of adjuvant chemotherapy treatment, which should be recommended for most patients.","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":"12 1","pages":"JCO2500621"},"PeriodicalIF":45.3,"publicationDate":"2026-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145937770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jason K Sicklick, Daisuke Nishizaki, Hirotaka Miyashita, Ryosuke Okamura, Michael E Hahn, Mina Nikanjam, Paul T Fanta, David E Piccioni, Hitendra Patel, Ramez N Eskander, Rana R McKay, Jeffrey S Ross, J Jack Lee, Scott M Lippman, Shumei Kato, Razelle Kurzrock
Purpose: Malignancies have complex and distinct molecular profiles that may not segregate by tumor type. However, most precision oncology treatments are matched to a single biomarker. We aimed to optimize therapy for advanced cancers using individually dosed drug regimens customized to cotarget multiple molecular alterations.
Methods: Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy (I-PREDICT; NCT02534675) is a prospective, investigator-initiated, multidepartment/pan-cancer trial for aggressive advanced/metastatic malignancies. Patients had tissue and/or blood next-generation sequencing (NGS; Foundation Medicine). A molecular tumor board made suggestions. Degree of biomarker matching to drugs given was calculated by a matching score (MS; broadly, number of pathogenic alterations targeted divided by total pathogenic alterations).
Results: Overall, 210 evaluable patients (n = 456 consented) received ≥1 US Food and Drug Administration-approved drug (mostly off label) after NGS. Median number of pathogenic alterations/tumor was five (range, 0-20); approximately 95% of patients had unique molecular landscapes. Consistent with I-PREDICT's objective to optimize/tailor treatment for each patient, we administered 157 different regimens (including 103 personalized combinations without established safety/dosing data). For previously unstudied combinations, starting doses were reduced and titrated to tolerance (intrapatient dose-finding); only 6.5% experienced Grade 3/4 drug-related toxicities (v 15.5% of those receiving established regimens). Higher disease control rate (stable disease ≥6 months/objective response), and longer progression-free survival and overall survival correlated significantly/independently/linearly with greater degrees of drug matching to alterations (higher MS), but did not vary by drug number or dosages.
Conclusion: The I-PREDICT strategy of maximizing personalized biomarker matching with individually dosed customized drug combinations enabled safe and active N-of-1 matched treatment, including regimens previously unstudied in Phase I trials. I-PREDICT represents a blueprint for a new personalized precision oncology paradigm, which merits validation via additional prospective trials.
{"title":"Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy (I-PREDICT) N-of-1 Precision Oncology Study: Molecular Profiling to Match Individually Dosed, Personalized Drug Combinations.","authors":"Jason K Sicklick, Daisuke Nishizaki, Hirotaka Miyashita, Ryosuke Okamura, Michael E Hahn, Mina Nikanjam, Paul T Fanta, David E Piccioni, Hitendra Patel, Ramez N Eskander, Rana R McKay, Jeffrey S Ross, J Jack Lee, Scott M Lippman, Shumei Kato, Razelle Kurzrock","doi":"10.1200/JCO-25-01453","DOIUrl":"https://doi.org/10.1200/JCO-25-01453","url":null,"abstract":"<p><strong>Purpose: </strong>Malignancies have complex and distinct molecular profiles that may not segregate by tumor type. However, most precision oncology treatments are matched to a single biomarker. We aimed to optimize therapy for advanced cancers using individually dosed drug regimens customized to cotarget multiple molecular alterations.</p><p><strong>Methods: </strong>Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy (I-PREDICT; NCT02534675) is a prospective, investigator-initiated, multidepartment/pan-cancer trial for aggressive advanced/metastatic malignancies. Patients had tissue and/or blood next-generation sequencing (NGS; Foundation Medicine). A molecular tumor board made suggestions. Degree of biomarker matching to drugs given was calculated by a matching score (MS; broadly, number of pathogenic alterations targeted divided by total pathogenic alterations).</p><p><strong>Results: </strong>Overall, 210 evaluable patients (n = 456 consented) received ≥1 US Food and Drug Administration-approved drug (mostly off label) after NGS. Median number of pathogenic alterations/tumor was five (range, 0-20); approximately 95% of patients had unique molecular landscapes. Consistent with I-PREDICT's objective to optimize/tailor treatment for each patient, we administered 157 different regimens (including 103 personalized combinations without established safety/dosing data). For previously unstudied combinations, starting doses were reduced and titrated to tolerance (intrapatient dose-finding); only 6.5% experienced Grade 3/4 drug-related toxicities (<i>v</i> 15.5% of those receiving established regimens). Higher disease control rate (stable disease ≥6 months/objective response), and longer progression-free survival and overall survival correlated significantly/independently/linearly with greater degrees of drug matching to alterations (higher MS), but did not vary by drug number or dosages.</p><p><strong>Conclusion: </strong>The I-PREDICT strategy of maximizing personalized biomarker matching with individually dosed customized drug combinations enabled safe and active N-of-1 matched treatment, including regimens previously unstudied in Phase I trials. I-PREDICT represents a blueprint for a new personalized precision oncology paradigm, which merits validation via additional prospective trials.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"JCO2501453"},"PeriodicalIF":41.9,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145933532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Reply to: Enhancing Representation and Reporting of Body Mass Index in Cancer Randomized Clinical Trials.","authors":"Stephanie B Wheeler","doi":"10.1200/JCO-25-02689","DOIUrl":"https://doi.org/10.1200/JCO-25-02689","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"JCO2502689"},"PeriodicalIF":41.9,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145933607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Enhancing Representation and Reporting of Body Mass Index in Cancer Randomized Clinical Trials.","authors":"Mei-An Nolan, Ludovic Trinquart","doi":"10.1200/JCO-25-02077","DOIUrl":"https://doi.org/10.1200/JCO-25-02077","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"JCO2502077"},"PeriodicalIF":41.9,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145933480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：